First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.

J. J. Ko, T. K. Choueiri, B. I. Rini, J. L. Lee, N. Kroeger, S. Srinivas, L. C. Harshman, J. J. Knox, G. A. Bjarnason, M. J. MacKenzie, L. Wood, U. N. Vaishampayan, N. Agarwal, S. K. Pal, M. H. Tan, S. Y. Rha, T. Yuasa, F. Donskov, A. Bamias, D. Y. Heng

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Limited data exist on outcomes for metastatic renal cell carcinoma (mRCC) patients treated with multiple lines of therapy. Benchmarks for survival are required for patient counselling and clinical trial design. Outcomes of mRCC patients from the International mRCC Database Consortium database treated with 1, 2, or 3+ lines of targeted therapy (TT) were compared by proportional hazards regression. Overall survival (OS) and progression-free survival (PFS) were calculated using different population inclusion criteria. In total, 2705 patients were treated with TT of which 57% received only first-line TT, 27% received two lines of TT, and 16% received 3+ lines of TT. Overall survival of patients who received 1, 2, or 3+ lines of TT were 14.9, 21.0, and 39.2 months, respectively, from first-line TT (P<0.0001). On multivariable analysis, 2 lines and 3+ lines of therapy were each associated with better OS (HR=0.738 and 0.626, P<0.0001). Survival outcomes for the subgroups were as follows: for all patients, OS 20.9 months and PFS 7.2 months; for those similar to eligible patients in the first-line ADAPT trial, OS 14.7 months and PFS 5.6 months; for those similar to patients in first-line TIVO-1 trial, OS 24.8 months and PFS 8.2 months; for those similar to patients in second-line INTORSECT trial, OS 13.0 months and PFS 3.9 months; and for those similar to patients in the third-line GOLD trial, OS 18.0 months and PFS 4.4 months. Patients who are able to receive more lines of TT live longer. Survival benchmarks provide context and perspective when interpreting and designing clinical trials.

Original languageEnglish
Pages (from-to)1917-1922
Number of pages6
JournalBritish journal of cancer
Volume110
Issue number8
DOIs
Publication statusPublished - 2014 Apr 15

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.'. Together they form a unique fingerprint.

  • Cite this

    Ko, J. J., Choueiri, T. K., Rini, B. I., Lee, J. L., Kroeger, N., Srinivas, S., Harshman, L. C., Knox, J. J., Bjarnason, G. A., MacKenzie, M. J., Wood, L., Vaishampayan, U. N., Agarwal, N., Pal, S. K., Tan, M. H., Rha, S. Y., Yuasa, T., Donskov, F., Bamias, A., & Heng, D. Y. (2014). First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. British journal of cancer, 110(8), 1917-1922. https://doi.org/10.1038/bjc.2014.25